VRDN

Viridian Therapeutics, Inc. [VRDN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VRDN Stock Summary

Top 10 Correlated ETFs

VRDN

Top 10 Correlated Stocks

VRDN

In the News

VRDN Financial details

Company Rating
-
Market Cap
997.38M
Income
-237.63M
Revenue
314K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
94
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-4.85
Forward P/E
-
PEG
-1.34
P/S
3591.61
P/B
3.65
P/C
-
P/FCF
-6.87
Quick Ratio
13.47
Current Ratio
13.93
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.32
EPS next Y
-
EPS next Q
-
EPS this Y
35.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-23.53%
Revenue last 5Y
-41.18%
Revenue Q/Q
-
EPS Q/Q
23.85%
-
-
-
-
SMA20
9.52%
SMA50
27.78%
SMA100
53.33%
Inst Own
-
Inst Trans
-
ROA
-65%
ROE
-63%
ROC
-0.76%
Gross Margin
100%
Oper. Margin
-66870%
Profit Margin
-61462%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.925-30.3
52W High
-21.07%
52W Low
+136.79%
RSI
61
Rel Volume
1.03
Avg Volume
948.34K
Volume
974.33K
Perf Week
8.12%
Perf Month
21.87%
Perf Quarter
80.48%
Perf Half Y
75.01%
-
-
-
-
Beta
1.098
-
-
Volatility
0.54%, 1.37%
Prev Close
2.91%
Price
23.679
Change
2.11%

Something similar

Top by Market Cap
VTI
ABEC.DE
BRK-A
VOO
BRH.DE
Top Correlated ETFs
BBC
XBI
LABU
IBRN
AMED.DE
Top Correlated Stocks
DNLI
XENE
XNCR
NUVL
ELET6.SA
Similar Market Cap
INDSWFTLTD.NS
CVSG.L
TAINWALCHM.NS
ALBO
XDV.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 948.34K
  • Market Capitalization 997.38M
  • Employee 94
  • CEO Mr. Stephen F. Mahoney J.D., MBA
  • Headquarters Waltham,MA,US
  • IPO Date 2014-06-18
  • Website https://www.viridiantherapeutics.com

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.